Skip to main content
SpringerLink
Log in

18F-FDG PET/CT in Lung Cancer

  • Chapter
  • First Online:
PET/CT in Lung Cancer

Part of the book series: Clinicians’ Guides to Radionuclide Hybrid Imaging ((PET/CT))

Abstract

[18F] 2-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT (positron emission tomography/computed tomography) is a non-invasive imaging modality which combines metabolic and anatomic information in evaluation of cancer. This is a useful imaging modality for staging of lung cancer, treatment response evaluation, radiotherapy planning, restaging and in prognostication of lung cancer. In this chapter we shall discuss these roles of 18F-FDG PET/CT in management of lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71.

    Article  PubMed  Google Scholar 

  2. Rodriguez E, Lilenbaum RC. Small cell lung cancer: past, present, and future. Curr Oncol Rep. 2010;12:327–34.

    Article  PubMed  Google Scholar 

  3. Ost D, Fein AM, Feinsilver SH. Clinical practice. The solitary pulmonary nodule. N Engl J Med. 2003;348(25):2535–42.

    Article  PubMed  Google Scholar 

  4. Visioni A, Kim J. Positron emission tomography for benign and malignant disease. Surg Clin North Am. 2001;91:249–66.

    Article  Google Scholar 

  5. Grgic A, Yüksel Y, Gröschel A, et al. Risk stratification of solitary pulmonary nodules bymeans of PET using (18)F-fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging. 2010;37:1087–94.

    Article  PubMed  Google Scholar 

  6. Fletcher JW, Kymes SM, Gould MK, et al. A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med. 2008;49:179–85.

    Article  PubMed  Google Scholar 

  7. Bradley J, Bae K, Choi N, Forster K, Siegel BA, Brunetti J, et al. A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys. 2012;82:435–41.e1.

    Article  PubMed  Google Scholar 

  8. Nestle U, Walter K, Schmidt S, Licht N, Nieder C, Motaref B, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 1999;44:593–7.

    Article  CAS  PubMed  Google Scholar 

  9. Pawaroo D, Cummings NM, Musonda P, Rintoul RC, Rassl D, Beadsmoore C. Non-small cell lung carcinoma: accuracy of PET/CT in determining the size of T1 and T2 primary tumors. AJR Am J Roentgenol. 2011;196:1176–18.

    Article  PubMed  Google Scholar 

  10. Kligerman S, Digumarthy S. Staging of non-small cell lung cancer using integrated PET/CT. AJR Am J Roentgenol. 2009;193:1203–11.

    Article  PubMed  Google Scholar 

  11. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, Detterbeck F. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:178S–201S.

    Article  PubMed  Google Scholar 

  12. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879–92.

    Article  PubMed  Google Scholar 

  13. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123(Suppl):137S–46S.

    Article  PubMed  Google Scholar 

  14. Fischer BM, Mortensen J, Højgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol. 2001;2:659–66.

    Article  CAS  PubMed  Google Scholar 

  15. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology. 1999;213:530–6.

    Article  CAS  PubMed  Google Scholar 

  16. Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol. 2011;6:1367–72.

    Article  PubMed  Google Scholar 

  17. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(Suppl):e211–50S.

    Article  Google Scholar 

  18. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET/CT. N Engl J Med. 2009;361:32–9.

    Google Scholar 

  19. Sahiner I, Vural GU. Positron emission tomography/computerized tomography in lung cancer. Quant Imaging Med Surg. 2014;4:195–206.

    PubMed  PubMed Central  Google Scholar 

  20. Quint LE. Staging non-small cell lung cancer. Cancer Imaging. 2007;7:148–59.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist. 2004;9:633–43.

    Article  PubMed  Google Scholar 

  22. Li J, Xu W, Kong F, Sun X, Zuo X. Meta-analysis: accuracy of 18FDG PET/CT for distant metastasis staging in lung cancer patients. Surg Oncol. 2013;22:151–5.

    Google Scholar 

  23. Kumar R, Xiu Y, Yu JQ, Takalkar A, El-Haddad G, Potenta S, Kung J, Zhuang H, Alavi A. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med. 2004;45:2058–62.

    PubMed  Google Scholar 

  24. Brady MJ, Thomas J, Wong TZ, Franklin KM, Ho LM, Paulson EK. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Radiology. 2009;250:523–30.

    Article  PubMed  Google Scholar 

  25. Cho AR, Lim I, Na II, du Choe H, Park JY, Kim BI, et al. Evaluation of adrenal masses in lung cancer patients using F-18 FDG PET/CT. Nucl Med Mol Imaging. 2011;45:52–8.

    Article  PubMed  Google Scholar 

  26. Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of 18FDG-PET/CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81:1007–15.

    Google Scholar 

  27. Chang MC, Chen JH, Liang JA, Lin CC, Yang KT, Cheng KY, et al. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer. Acad Radiol. 2012;19:349–57.

    Article  PubMed  Google Scholar 

  28. Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248:632–42.

    Article  PubMed  Google Scholar 

  29. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol. 2000;175:245–9.

    Article  CAS  PubMed  Google Scholar 

  30. Gupta NC, Rogers JS, Graeber GM, Gregory JL, Waheed U, Mullet D, Atkins M. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest. 2002;122:1918–24.

    Article  CAS  PubMed  Google Scholar 

  31. Light RW, Erozan YS, Ball WC. Cells in pleural fluid. Their value in differential diagnosis. Arch Intern Med. 1973;132:854–60.

    Article  CAS  PubMed  Google Scholar 

  32. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011–9.

    Article  PubMed  Google Scholar 

  33. De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, et al. Additional value of PET/CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007;17:23–32.

    Google Scholar 

  34. Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596–604.

    CAS  PubMed  Google Scholar 

  35. Pommier P, Touboul E, Chabaud S, Dussart S, Le Pechoux C, Giammarile F, et al. Impact of (18) F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: a prospective multicenter study. AJR Am J Roentgenol. 2010;195:350–5.

    Article  PubMed  Google Scholar 

  36. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59:78–86.

    Article  PubMed  Google Scholar 

  37. Skoura E, Datseris IE, Platis I, Oikonomopoulos G, Syrigos KN. Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non-small-cell lung cancer. Clin Lung Cancer. 2012;13:181–7.

    Article  PubMed  Google Scholar 

  38. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031–9.

    Article  CAS  PubMed  Google Scholar 

  39. Park JO, Lee SI, Song SY, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol. 2003;33:533–7.

    Article  PubMed  Google Scholar 

  40. de Geus-Oei L, van der Heijden H, Visser PE, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med. 2007;48:1592–8.

    Article  PubMed  Google Scholar 

  41. Koenig TR, Munden RF, Erasmus JJ, Sabloff BS, Gladish GW, Komaki R, et al. Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol. 2002;178:1383–8.

    Article  PubMed  Google Scholar 

  42. Larici AR, del Ciello A, Maggi F, Santoro SI, Meduri B, Valentini V, et al. Lung abnormalities at multimodality imaging after radiation therapy for non-small cell lung cancer. Radiographics. 2011;31:771–89.

    Article  PubMed  Google Scholar 

  43. Hellwig D, Gröschel A, Graeter TP, Hellwig AP, Nestle U, Schäfers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33:13–21.

    Article  PubMed  Google Scholar 

  44. He YQ, Gong HL, Deng YF, Li WM. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. Acta Radiol. 2014;55:309–17.

    Article  PubMed  Google Scholar 

  45. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136–43.

    Article  CAS  PubMed  Google Scholar 

  46. Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol. 2014;9:834–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37:691–8.

    Article  PubMed  Google Scholar 

  48. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE 2nd, Patz EF Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008;26:1459–64.

    Article  PubMed  Google Scholar 

  49. Park SY, Cho A, Yu WS, Lee CY, Lee JG, Kim DJ, et al. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer. J Nucl Med. 2015;56:45–9.

    Article  CAS  PubMed  Google Scholar 

  50. Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, et al. Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42:241–51.

    Article  CAS  PubMed  Google Scholar 

  51. Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS One. 2016;11(1):e0146195.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Lu YY, Chen JH, Liang JA, Chu S, Lin WY, Kao CH. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014;35:697–703.

    Article  CAS  PubMed  Google Scholar 

  53. Azad A, Chionh F, Scott AM, Lee ST, Berlangieri SU, White S, et al. High impact of 18F-FDG PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol. 2010;12:433–51.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, India

    Archi Agrawal MBBS, DMRE, DRM, DNB, Venkatesh Rangarajan MBBS, DRM, DNB & Nilendu Purandare MBBS, DMRD, DNB

Authors
  1. Archi Agrawal MBBS, DMRE, DRM, DNB
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Venkatesh Rangarajan MBBS, DRM, DNB
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nilendu Purandare MBBS, DMRD, DNB
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Archi Agrawal MBBS, DMRE, DRM, DNB .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine & Molecular Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India

    Archi Agrawal

  2. Department of Nuclear Medicine & Molecular Imaging, Tata Memorial Hospital, Mumbai, Maharashtra, India

    Venkatesh Rangarajan

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Agrawal, A., Rangarajan, V., Purandare, N. (2018). 18F-FDG PET/CT in Lung Cancer. In: Agrawal, A., Rangarajan, V. (eds) PET/CT in Lung Cancer. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-72661-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-72661-8_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-72660-1

  • Online ISBN: 978-3-319-72661-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation